Leucrose
Based on 1 Customer Validation
Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active Sucrose (HY-B1779) isomer naturally found in pollen and honey. Leucrose promotes phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokinesas (TNFα, and IL-1β), increases M2 macrophage polarization and suppresses DSS (HY-116282C)-induced colitis. Leucrose suppresses hepatic triglyceride accumulation, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice. Leucrose is slowly hydrolyzed into glucose and fructose by α-glucosidase and acts as as a sugar substitute in diet.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.53%
- CAS. Nr.: 7158-70-5
- Formel: C12H22O11
- Molecular Weight:342.30
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
JAK1 |
STAT6 |
IL-1β |
In Vitro
Leucrose (24 h) does not alter RAW 264.7 macrophage cell viability relative to glucose treatment in DMEM containing IL4 (20 ng/mL) and total glucose
content (25 mM) partially substituted with leucrose, but upregulates M2 macrophage markers (CD163, Arg1) and increases JAK1/STAT6 phosphorylation[1].
Leucrose is hydrolyzed into
glucose and fructose by α-glucosidase in the small intestine and suppresses adipogenesis and down-regulates adipogenesis-related gene expression in 3T3-L1 adipocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW 264.7 macrophage cells
-
Concentration:25% substitution of 25 mM glucose content; 50% substitution of 25 mM glucose content
-
Incubation Time:24 h
-
Result:Significantly exceeds levels in the non-treated control group across all treated groups.
Shows no significant difference between leucrose-treated groups (25% and 50% substitution) and the glucose-treated group.
-
Cell Line:RAW 264.7 macrophage cells
-
Concentration:25% substitution of 25 mM glucose content; 50% substitution of 25 mM glucose content
-
Incubation Time:24 h (with 20 ng/mL IL-4)
-
Result:Increases CD163 levels by 99.0% in the 50% leucrose substitution group compared to the high-glucose control group.
Increases Arg1 levels by 78.6% in the 50% leucrose substitution group compared to the high-glucose control group.
Significantly increases p-JAK1 levels in both the 25% and 50% leucrose substitution groups compared to the high-glucose control group.
Significantly increases p-STAT6 levels in both the 25% and 50% leucrose substitution groups compared to the high-glucose control group.
In Vivo
Leucrose (25-50% of total sucrose replaced; p.o.; ad libitum in diet; 12 weeks) improves fasting blood glucose levels, reduces hepatic triglyceride accumulation, downregulates hepatic lipogenesis-related genes, and upregulates hepatic β-oxidation-related genes in obese mice, with the 50% replacement showing greater potency for hepatic triglyceride reduction and β-oxidation gene activation[2].
Leucrose (25% indiet; p.o.; daily; 6 weeks) supports normal growth in weanling male SPF-Sprague-Dawley rats, with body weight gain, protein efficiency, and energy efficiency statistically equivalent to sucrose or corn starch controls[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 5-week-old, 18-20 g, DSS-induced colitis model)[1]
-
Dosage:25% of total sucrose content replaced with leucrose; 50% of total sucrose content replaced with leucrose
-
Administration:p.o.; ad libitum in diet; continuously for 5 weeks
-
Result:Attenuated DAI scores at day 19 by 59.2% (25% replacement) and 56.9% (50% replacement) compared to the DSS-only group.
Suppressed DAI area under the curve (AUC) scores by 25.4% (25% replacement) and 37.3% (50% replacement) compared to the DSS-only group.
Restored colon length by 12.6% (25% replacement) and 20.3% (50% replacement) compared to the DSS-only group.
Reduced myeloperoxidase (MPO) activity by 30.4% (25% replacement) and 31.9% (50% replacement) compared to the DSS-only group.
Reduced colon tissue iNOS protein levels by 89.3% (50% replacement) and COX2 protein levels by 84.0% (50% replacement) compared to the DSS-only group.
Down-regulated colon tissue mRNA levels of MCP-1, TNFα, and IL-1β by 44.7%, 34.7%, and 81.1% respectively in the 50% replacement group compared to the DSS-only group.
Reduced plasma IL-1β concentrations by 36.9% (25% replacement) and 34.4% (50% replacement) compared to the DSS-only group.
Significantly reduced colon tissue F4/80-positive macrophage infiltration compared to the DSS-only group in both leucrose groups.
Significantly increased colon tissue mRNA levels of M2 polarization markers Arg1 and Ym1 in both leucrose groups, and CD206 in the 50% replacement group only, compared to the DSS-only group.
-
Animal Model:C57BL/6 (5-week-old male, 18-20 g, high-fat diet-induced obesity model)[2]
-
Dosage:25% of total sucrose replaced with leucrose; 50% of total sucrose replaced with leucrose
-
Administration:p.o.; ad libitum in diet; 12 weeks
-
Result:Reduced fasting blood glucose levels to 141 mg/dL (L25 group) and 133 mg/dL (L50 group), compared to HFD control's 184 mg/dL.
Reduced hepatic triglyceride content to 70 mg/g in L50 group compared to HFD control; L25 group showed non-significant reduction.
Downregulated peroxisome proliferator-activated receptor γ (Pparg) in L25 and L50 groups; downregulated sterol regulatory element binding protein 1C (Srebf1) in both leucrose groups; fatty acid synthase (Fasn) showed non-significant downward trend.
Upregulated peroxisome proliferator-activated receptor α (Ppara) and acyl CoA oxidase (Acox1) in L50 group; upregulated carnitine palmitoyltransferase 1A (Cpt1a) in both L25 and L50 groups, reversing HFD-induced downregulation.
Chemical Information
-
CAS. Nr. 7158-70-5
-
Appearance Solid
-
Molecular Weight 342.30
-
Formel C12H22O11
-
Color White to off-white
-
SMILES
OCC([C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]([C@H]([C@@H]([C@H]1O)O)O)CO)=O
-
Synonyms
5-O-α-D-Glucopyranosyl-D-fructose
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
In Vitro:
H2O : 70 mg/mL (204.50 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Primary monocyte-to-macrophage differentiation
Primary human monocytes can be differentiated ex vivo into monocyte-derived macrophages by culturing purified blood monocytes for approximately 5-7 days in macrophage-supporting cytokine conditions; M-CSF commonly yields CD14^high/CD163^high macrophages, while GM-CSF yields a phenotypically distinct macrophage population, so the cytokine condition should be chosen according to the downstream model. The readout of successful differentiation is a combined change in morphology, adherence, surface phenotype, and function: differentiated macrophages become adherent, enlarge, acquire macrophage-associated markers such as CD14, CD68, CD163, CD206, or HLA-DR depending on culture condition, and show increased phagocytic capacity compared with starting monocytes.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Reinheit & Dokumentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.9214 mL | 14.6071 mL | 29.2141 mL | 73.0354 mL |
| 5 mM | 0.5843 mL | 2.9214 mL | 5.8428 mL | 14.6071 mL | |
| 10 mM | 0.2921 mL | 1.4607 mL | 2.9214 mL | 7.3035 mL | |
| 15 mM | 0.1948 mL | 0.9738 mL | 1.9476 mL | 4.8690 mL | |
| 20 mM | 0.1461 mL | 0.7304 mL | 1.4607 mL | 3.6518 mL | |
| 25 mM | 0.1169 mL | 0.5843 mL | 1.1686 mL | 2.9214 mL | |
| 30 mM | 0.0974 mL | 0.4869 mL | 0.9738 mL | 2.4345 mL | |
| 40 mM | 0.0730 mL | 0.3652 mL | 0.7304 mL | 1.8259 mL | |
| 50 mM | 0.0584 mL | 0.2921 mL | 0.5843 mL | 1.4607 mL | |
| 60 mM | 0.0487 mL | 0.2435 mL | 0.4869 mL | 1.2173 mL | |
| 80 mM | 0.0365 mL | 0.1826 mL | 0.3652 mL | 0.9129 mL | |
| 100 mM | 0.0292 mL | 0.1461 mL | 0.2921 mL | 0.7304 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Keywords
- Leucrose
- 7158-70-5
- 5-O-α-D-Glucopyranosyl-D-fructose
- JAK
- STAT
- TNF Receptor
- Interleukin Related
- JAK1/STAT6 signaling pathway
- SPF-Sprague-Dawley rats
- RAW 264.7 macrophages
- STAT6
- dextran sulfate sodium-induced colitis
- C57BL/6 mice
- non-alcoholic fatty liver disease
- JAK1
- M2 macrophage polarization
- 3T3-L1 adipocytes
- Inhibitor
- inhibitor
- inhibit